Virus Destroying Or Inhibiting Patents (Class 514/3.7)
-
Patent number: 8633198Abstract: Antiviral compositions and methods are contemplated that are especially effective in the treatment and prevention of influenza A viruses. Also presented are cellular assays to identify small molecule compounds having antiviral properties, particularly as it relates to detection of influenza A RNA-dependent RNA polymerase activity in a mammalian cell independent of other influenza A components. Preferred assays allow for identification of viral replication inhibitors that do not disrupt normal cellular activity.Type: GrantFiled: September 19, 2012Date of Patent: January 21, 2014Assignee: Nant Holdings IP, LLCInventors: Kayvan Niazi, Shahrooz Rabizadeh, Anne-Laure Le Ny, Oleksandr Buzko, Justin Golovato, Patrick Soon-Shiong
-
Publication number: 20140011734Abstract: The present invention relates to compounds of the Formula (I), in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, X1, X2, X3 and X4 have the meanings indicated in the claims, and which are valuable pharmacologically active compounds. They are reversible inhibitors of the interaction between the plasma protein von Willebrand factor (vWF) and the blood platelet receptor glycoprotein Ib-IX-V complex (GPIb), and are suitable, for example, for the therapy and prophylaxis of athero-thrombotic diseases. The invention furthermore relates to processes for the preparation of compounds of the Formula (I), their use, in particular as active ingredients in medicaments, and pharmaceutical compositions comprising them.Type: ApplicationFiled: July 27, 2011Publication date: January 9, 2014Applicant: SANOFIInventors: Otmar Klingler, Horst Blum, Andreas Lindenschmidt, Hans Matter
-
Publication number: 20140011735Abstract: The present invention provides a composition comprising a broad spectrum protein of microbial origin as active anti-HIV/AIDS agent. Either the protein is secreted by or surface associated in microorganisms including but not limiting to bacteria, both pathogenic and non-pathogenic. The proteins used are isolated from bacteria Mycobacterium spp. specifically from Mycobacterium tuberculosis or M. bovis BCG. Further, the protein could be substituted by various truncated derivatives thereof, peptides derived from such proteins, synthetically prepared peptides, and proteins or peptides modified by PEGylation, acetylation, and phosphorylation. The protein includes purified proteins and peptides having amino acid sequence of SEQ ID No. 1 and 2 respectively.Type: ApplicationFiled: March 5, 2012Publication date: January 9, 2014Applicant: AMRITA THERAPEUTICS LIMITEDInventors: Mendes, Fialho Arsenio Do Carmo Sales, Filipe Santos Bernardes Nuno, Braz Gonçalves João Manuel, Cunha Santos Ana Catarina
-
Patent number: 8623815Abstract: New mutant forms of TRIM5? comprising one or more mutations at amino acid positions corresponding to amino acids 324, 328, 330, 333, 335, 336 and/or 337 of wild-type human TRIM5? and which inhibit retrovirus replication are described. These mutants may be used, for example, in gene therapy applications for the prevention and/or treatment of retroviral infection and associated conditions, such as HIV-1 infection and AIDS.Type: GrantFiled: November 19, 2010Date of Patent: January 7, 2014Assignee: Université du Québec à Trois-RivirèresInventors: Lionel Berthoux, Amélie Bouchard, Quang Toan Pham
-
Patent number: 8623814Abstract: The present invention provides antiviral compounds of formula (I), as well as pharmaceutical compositions comprising these compounds, methods for synthesizing these compounds and methods of using these compounds for treating a viral infection.Type: GrantFiled: February 23, 2011Date of Patent: January 7, 2014Assignee: Enanta Pharmaceuticals, Inc.Inventors: Yat Sun Or, In Jong Kim, Guoqiang Wang, Jiang Long
-
Publication number: 20140005102Abstract: The invention describes novel pharmaceutical compositions for the treatment of virus infections and cancer. The pharmaceutical compositions include mutant oligoadenylate synthetases (OAS) that have either enhanced cell permeability, reduced oxidative potential, improved antiviral activity, improved enzymatic activity, or absent enzymatic activity. The pharmaceutical compositions have improved drug properties and retain or have enhanced antiviral activity relative to their native forms. The pharmaceutical compositions further include chemically modified oligoadenylate synthetases, such chemical modifications being designed to increase serum stability and reduce immunogenicity in vivo. Such chemical modifications further increase drug stability and manufacturability in vitro. Compositions composed of more than ninety novel modifications are described. Also described are antibodies to polypeptides of the invention.Type: ApplicationFiled: July 1, 2013Publication date: January 2, 2014Applicant: Kineta Two LLCInventors: Shawn P. Iadonato, Charles L. Magness, Mark Branum, Maralee McVean, Christina Scherer
-
Publication number: 20140005100Abstract: The present invention relates to a compound of the formula (I), (II), (III), (IV), (V), or (VI) or pharmaceutically acceptable salt thereof, wherein the symbols are as defined in the specification; a pharmaceutical composition comprising the same, a method for treating or preventing a viral infection using the same.Type: ApplicationFiled: August 12, 2011Publication date: January 2, 2014Inventors: Zhuang Su, Zhengyu Long, Zhennian Huang, Suizhou Yang
-
Publication number: 20140005101Abstract: The invention describes novel pharmaceutical compositions for the treatment of virus infections and cancer. The pharmaceutical compositions include mutant oligoadenylate synthetases (OAS) that have either enhanced cell permeability, reduced oxidative potential, improved antiviral activity, improved enzymatic activity, or absent enzymatic activity. The pharmaceutical compositions have improved drug properties and retain or have enhanced antiviral activity relative to their native forms. The pharmaceutical compositions further include chemically modified oligoadenylate synthetases, such chemical modifications being designed to increase serum stability and reduce immunogenicity in vivo. Such chemical modifications further increase drug stability and manufacturability in vitro. Compositions composed of more than ninety novel modifications are described. Also described are antibodies to polypeptides of the invention.Type: ApplicationFiled: June 14, 2013Publication date: January 2, 2014Applicant: Kineta Two LLCInventors: Shawn P. Iadonato, Charles L. Magness, Mark Branum, Maralee McVean, Christina Scherer
-
Publication number: 20130344029Abstract: Provided are compounds of Formula I: and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of virus infections, particularly hepatitis C infections.Type: ApplicationFiled: June 7, 2013Publication date: December 26, 2013Inventors: Caroline Aciro, Victoria Alexandra Steadman, Simon Neil Pettit, Karine G. Poullennac, Linos Lazarides, David Kenneth Dean, Neil Andrew Dunbar, Adrian John Highton, Andrew John Keats, Dustin Scott Siegel, Kapil Kumar Karki, Adam James Schrier, Petr Jansa, Richard Mackman
-
Publication number: 20130344030Abstract: Provided are compounds of Formula I: and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of virus infections, particularly hepatitis C infections.Type: ApplicationFiled: June 7, 2013Publication date: December 26, 2013Inventors: Victoria Alexandra Steadman, Karine G. Poullennec, Linos Lazarides, Caroline Aciro, David Kenneth Dean, Andrew John Keats, Dustin Scott Siegel, Adam James Schrier, Richard Mackman, Petr Jansa
-
Publication number: 20130337050Abstract: A peptide, wherein the peptide comprises an amino acid sequence expressed by the following SEQ ID NO: 1, an amino acid sequence expressed by the following SEQ ID NO: 2, an amino acid sequence expressed by the following SEQ ID NO: 3, an amino acid sequence expressed by the following SEQ ID NO: 4, or any combination thereof: (SEQ?ID?NO:?1) ALGDSLYGAASLN; (SEQ?ID?NO:?2) MTVDNPASTTNKDKLFSVWK; (SEQ?ID?NO;?3) PGAVPEK; and (SEQ?ID?NO:?4) STKDLTTY.Type: ApplicationFiled: July 31, 2013Publication date: December 19, 2013Applicants: ImmunoFuture, Inc., Microbial Chemistry Research FoundationInventors: Akio NOMOTO, Coh-ichi NIHEI
-
Patent number: 8609105Abstract: Drug Linker compounds and Drug Linker Ligand conjugates are provided that have auristatins linked via the C-terminus. The conjugates show efficacy without the need for a self-immolative group to release the drug.Type: GrantFiled: March 18, 2009Date of Patent: December 17, 2013Assignee: Seattle Genetics, Inc.Inventors: Peter Senter, Svetlana Doronina, Timothy Bovee
-
Publication number: 20130331313Abstract: Provided are methods and compositions for the prevention and/or treatment of viral conditions, virally-induced conditions and inflammatory conditions. The methods can comprise administering to a subject a viral inducing agent with an antiviral agent, and optionally an additional agent. The viral inducing agent can be a HDAC inhibitor administered orally.Type: ApplicationFiled: June 7, 2013Publication date: December 12, 2013Inventors: Ronald J. Berenson, Douglas V. Faller
-
Publication number: 20130331310Abstract: This invention describes an ICE inhibitor prodrug (I) having good bioavailability. Compound I is useful for treating IL-1 mediated diseases such as rheumatoid arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, inflammatory peritonitis, septic shock, pancreatitis, traumatic brain injury, organ transplant rejection, osteoarthritis, asthma, psoriasis, Alzheimer's disease, myocardial infarction, congestive heart failure, Huntington's disease, atherosclerosis, atopic dermatitis, leukemias and related disorders, myelodysplastic syndrome, uveitis or multiple myeloma.Type: ApplicationFiled: December 10, 2012Publication date: December 12, 2013Inventor: Vertex Pharmaceuticals Incorporated
-
Patent number: 8603965Abstract: Pharmaceutical compositions for the prophylaxis and treatment of HIV infection and its use are provided. Particularly, the present invention provides a pharmaceutical composition comprising anti-virus peptides, use of said composition for manufacturing a medicament for the prophylaxis and treatment of HIV infection, and method for preventing and treating HIV infection by using said composition.Type: GrantFiled: June 12, 2007Date of Patent: December 10, 2013Assignee: FusoGen Pharmaceuticals, Inc.Inventors: Genfa Zhou, Qing Liang, Dan Ju
-
Publication number: 20130324459Abstract: Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation.Type: ApplicationFiled: March 12, 2013Publication date: December 5, 2013Applicant: ONYX THERAPEUTICS, INC.Inventor: Onyx Therapeutics, Inc.
-
Patent number: 8598116Abstract: The present invention provides methods for the treatment of an ongoing influenza infection by administering a polypeptide to a subject suffering from an influenza infection. The polypeptide consists of SEQ ID NO: 4. The present invention also provides a method of interfering with fusion of an influenza virus envelope with a host cell membrane by contacting the host cell with a polypeptide consisting of SEQ ID NO: 4.Type: GrantFiled: May 29, 2012Date of Patent: December 3, 2013Assignees: The Administrators of the Tulane, Educational Fund and Autoimmune Technologies, LLCInventors: Robert F. Garry, Russell B. Wilson
-
Patent number: 8592368Abstract: The present invention concerns a method for treating or reducing the likelihood of developing a respiratory syncytial virus (RSV) infection in a subject by administering an effective amount of an inhibitor of the janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling pathway or the mitogen-activated kinase (MAPK)/extracellular signal-regulated kinase (ERK1/2) signaling pathway to the subject. Another aspect of the invention concerns a pharmaceutical composition that includes an inhibitor of JAK/STAT or MAPK/ERK signaling to the subject; and a pharmaceutically acceptable carrier. Another aspect of the invention concerns a method for identifying agents useful for treating or reducing the likelihood of developing an RSV infection.Type: GrantFiled: December 20, 2004Date of Patent: November 26, 2013Assignee: University of South FloridaInventor: Shyam S. Mohapatra
-
Publication number: 20130310309Abstract: A topical pharmaceutical composition for treating a skin disorder selected from the group consisting of Herpes viral infection, Varicella viral infection, rash, insect bites, jellyfish stings, burns, psoriasis, itching, skin allergic response, skin lesions as a result of drug or medical treatment side effects or complications, and hypopigmantation. The composition comprises a peptide of the formula pGLU-X—Y—Z, where X, Y and Z are amino acids, with or without an alkyl group, and a pharmaceutically acceptable excipient.Type: ApplicationFiled: March 25, 2012Publication date: November 21, 2013Applicant: S.I.S. Shulov Innovative Science Ltd.Inventor: Naftali Primor
-
Publication number: 20130302351Abstract: The disclosure relates to inhibition of the VIP signaling pathway. In certain embodiments, the disclosure relates to methods of treating or preventing a viral infection comprising administering a VIP antagonist to a subject in need thereof.Type: ApplicationFiled: January 31, 2012Publication date: November 14, 2013Applicant: EMORY UNIVERSITYInventors: Edmund K. Waller, Jian-Ming Li, Mohammad S. Hossain
-
Publication number: 20130302357Abstract: The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepines of formula (I) and (II), in which the diazepine ring (B) is fused with a heterocyclic ring (CD), wherein the heterocyclic ring is bicyclic or a compound of formula (III), in which the diazepine ring (B) is fused with a heterocyclic ring (C), wherein the heterocyclic ring is monocyclic. The invention provides cytotoxic dimers of these compounds. The invention also provides conjugates of the monomers and the dimers. The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention. The invention further relates to methods of using the compounds or conjugates for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.Type: ApplicationFiled: March 14, 2013Publication date: November 14, 2013Inventors: Wei Li, Nathan Elliott Fishkin, Robert Yongxin Zhao, Michael Louis Miller, Ravi V.J. Chari
-
Publication number: 20130281362Abstract: The present invention proposes a combination of bis-(gamma-L-glutamyl)-L-cysteinyl-glycine or a salt thereof, inosine and coordination compounds formed by palladium, copper and (gamma-L-glutamyl)-L-cysteinyl-glycine; a pharmaceutical composition and an anti-viral agent based on said combination, and also a method for treatment of a viral disease.Type: ApplicationFiled: December 30, 2011Publication date: October 24, 2013Applicant: "IVY PHARM" LIMITED LIABILITY COMPANYInventors: Mark Borisovich Balazovsky, Viktor Georgievich Antonov, Alexandr Nikolaevich Belyaev, Alexei Vladimirovich Eremin
-
Publication number: 20130280297Abstract: The invention provides immunomodulatory proteins, e.g., useful to prevent, inhibit or treat microbial infection.Type: ApplicationFiled: March 14, 2013Publication date: October 24, 2013Inventors: Lori Neal, Laura Knoll, Erik Settles, Lindsey Anne Moser
-
Publication number: 20130280262Abstract: The present invention provides polypeptides and compositions thereof for treating or limiting respiratory syncytial virus infection, and computational methods for designing such polypeptides.Type: ApplicationFiled: October 6, 2011Publication date: October 24, 2013Applicant: University of Washington Through Its Center For CommercializationInventors: William R. Schief, Bruno E. Correia, David Baker
-
Publication number: 20130281361Abstract: The present invention relates to methods of treating or preventing non-enveloped viral infection and/or disease caused by non-enveloped virus infection, particularly a viral infection caused by rhino virus. The methods comprise administering to an individual in need thereof an effective amount of a defensin peptide. The defensin peptide may be selected from ?-, ?-, or ?-defensins.Type: ApplicationFiled: November 4, 2011Publication date: October 24, 2013Applicant: PULMATRIX, INC.Inventors: David L. Hava, Robert W. Clarke
-
Patent number: 8563505Abstract: Hepatitis C virus inhibitors having the general formula are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.Type: GrantFiled: September 24, 2009Date of Patent: October 22, 2013Assignee: Bristol-Myers Squibb CompanyInventors: Sheldon Hiebert, Michael S. Bowsher, Ramkumar Rajamani, Rongti Li, Paul Michael Scola
-
Patent number: 8563506Abstract: Novel peptides that inhibit the release of microparticles from cells are disclosed. The peptide contains at least one VGFPV motif at the N-terminal and has a length of 10-100 amino acids. Also disclosed is polynucleotide encoding the peptide, expression vectors carrying the polynucleotide, and methods for treating AIDS and tumors using the novel peptides.Type: GrantFiled: December 4, 2012Date of Patent: October 22, 2013Assignee: Morehouse School of MedicineInventors: Vincent Craig Bond, Michael Powell, Ming Bo Huang, Syed Ali, Andrea D. Raymond, Martin Neville Shelton, Francois Jean Villinger
-
Publication number: 20130274176Abstract: This application describes a family of compounds acting as ?-arrestin effectors. Such compounds may provide significant therapeutic benefit in the treatment of chronic and acute cardiovascular diseases.Type: ApplicationFiled: June 24, 2013Publication date: October 17, 2013Applicant: Trevena, Inc.Inventors: Dennis Yamashita, Xiao-Tao Chen
-
Publication number: 20130267461Abstract: The invention is concerned with methods, compounds and pharmaceutical compositions for interfering dendritic cell immunoreceptor (DCIR) activity and signalling events. Described herein are compounds useful in targeting one or more of intracellular modulators and the uses thereof for the prevention or treatment of virus infections, and more particularly for reducing human immunodeficiency virus (HIV) binding, entry and/or replication in human cells. Exemplary compounds include peptides and antisense molecules.Type: ApplicationFiled: August 4, 2011Publication date: October 10, 2013Applicant: Universite LavalInventors: Caroline Gilbert, Alexandra Lambert, Michel J. Tremblay
-
Publication number: 20130267460Abstract: The invention provides methods of inhibiting alphavirus replication and treating alphavirus infection.Type: ApplicationFiled: September 16, 2011Publication date: October 10, 2013Applicant: The Johns Hopkins UniversityInventors: Diane E. Griffin, Michael Ayars
-
Patent number: 8551943Abstract: Novel peptides that inhibit the release of microparticles from cells are disclosed. The peptide contains at least one VGFPV motif at the N-terminal and has a length of 10-100 amino acids. Also disclosed is polynucleotide encoding the peptide, expression vectors carrying the polynucleotide, and methods for treating AIDS and tumors using the novel peptides.Type: GrantFiled: September 17, 2012Date of Patent: October 8, 2013Assignee: Morehouse School of MedicineInventors: Vincent Craig Bond, Michael Powell, Ming Bo Huang, Syed Ali, Andrea D. Raymond, Martin Neville Shelton, Francois Jean Villinger
-
ALPHABODIES SPECIFICALLY BINDING TO CLASS-I VIRAL FUSION PROTEINS AND METHODS FOR PRODUCING THE SAME
Publication number: 20130261049Abstract: Single-chain Alphabodies that comprise an alpha-helical binding region which mediates binding to a first fusion-driving region of a class-1 viral fusion protein and which structurally mimics a second fusion-driving region of said class-1 viral fusion protein, wherein said first and second fusion-driving regions of said class-1 viral fusion protein are regions which interact to drive the fusion between a virus displaying said class-1 viral fusion protein and a target cell.Type: ApplicationFiled: December 2, 2011Publication date: October 3, 2013Applicant: COMPLIX SAInventors: Johan Desmet, Ignace Lasters, Geert Meersseman, Sabrina Deroo -
Publication number: 20130261048Abstract: Described is a composition comprising—a peptide which consists of 7-17 adjacent amino acids and comprises the hexamer TX1EX2X3E, where X1, X2 and X3 can be any natural or non-natural amino acid, and the peptide is cyclized and does not exhibit TNF receptor binding activity, and—an inhibitor of viral neuraminidase.Type: ApplicationFiled: November 15, 2011Publication date: October 3, 2013Applicant: Apeptico Forschung UND Entwicklung GMBHInventors: Bernhard Fischer, Rudolf Lucas, Hendrik Fischer
-
Publication number: 20130251698Abstract: The present invention discloses a composition and method for effecting various cytokines and NF-?B by administering an effective amount of a phyto-percolate composition to an individual. In various exemplary embodiments, the composition is claimed to be useful for the effective treatment of inflammation, cancer, and/or various infections including HIV by regulation of various interleukins, such as IL-10 and IL-2, and of transcription factors including NF-?B.Type: ApplicationFiled: March 15, 2013Publication date: September 26, 2013Applicant: Health Enhancement Products, Inc.Inventors: Tiffany Thomas, Fazlul Sarkar, Denis Callewaert, Andrew Dahl, Enrique Martinez
-
Publication number: 20130251790Abstract: The present invention provides a pharmaceutical composition comprising a low dose of zanamivir and a process for preparing the pharmaceutical composition comprising a low dose of zanamivir. The pharmaceutical composition comprising a low dose zanamivir may be used in the treatment and/or prophylaxis of influenza. The present invention also provides a method of treatment and/or prophylaxis of influenza which comprises administering a dry powder inhaler composition comprising a low dose zanamivir. The pharmaceutical composition of the present invention comprises zanamivir and one or more pharmaceutically acceptable excipients, wherein the total daily dose of the zanamivir is less than 10 mg, preferably for administration at least once a day, and preferably wherein the composition delivers from 3 mg to 8 mg of zanamivir per administered dose.Type: ApplicationFiled: September 26, 2011Publication date: September 26, 2013Applicant: CIPLA LIMITEDInventors: Geena Malhotra, Shrinivas Madhukar Purandare
-
Publication number: 20130252880Abstract: Novel dendrimeric peptide compounds are disclosed that have a formula represented by the following formula I: The compounds demonstrate antimicrobial activity and may be prepared as pharmaceutical compositions and used for the prevention and treatment of a variety of conditions in mammals including humans where microbial invasion is involved. The present peptides are particularly valuable as their effect is rapid, broad in spectrum and mostly indifferent to resistance provoked by standard antibiotics.Type: ApplicationFiled: February 19, 2013Publication date: September 26, 2013Applicant: NEW YORK UNIVERSITY SCHOOL OF MEDICINEInventor: NEW YORK UNIVERSITY SCHOOL OF MEDICINE
-
Patent number: 8541377Abstract: The invention relates peptide entry inhibitors and methods of determining such inhibitors that are bindable to regions of viruses having class II E proteins, such as the dengue virus E protein, as candidates for in vivo anti-viral compounds.Type: GrantFiled: July 11, 2008Date of Patent: September 24, 2013Assignee: Florida Gulf Coast UniversityInventors: Scott F. Michael, Sharon Isern, Robert Garry, Ram Samudrala, Joshua Costin, Ekachai Jenwitheesuk
-
Patent number: 8536136Abstract: The present invention relates to compounds of formula I: or a pharmaceutically acceptable salt or mixtures thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection and to processes for preparing the compounds. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.Type: GrantFiled: December 16, 2009Date of Patent: September 17, 2013Assignee: Vertex Pharmaceuticals IncorporatedInventors: David Deininger, John Court, Luc Farmer, Janos Pitlik, Kevin Cottrell, Robert B. Perni
-
Publication number: 20130237474Abstract: Modified biosynthetic polypeptide fusion inhibitors, methods for manufacturing, and uses thereof are provided.Type: ApplicationFiled: November 13, 2012Publication date: September 12, 2013Applicant: AMBRX, INC.Inventors: Roberto Mariani, Bruce E. Kimmel
-
Publication number: 20130236553Abstract: The present invention provides compositions and methods for the delivery of therapeutics to a cell or subject.Type: ApplicationFiled: November 2, 2011Publication date: September 12, 2013Applicant: Board of Regents of the University of NebraskaInventors: Howard E. Gendelman, Alexander V. Kabanov, Xin-Ming Liu
-
Publication number: 20130236496Abstract: The present invention relates to the use of leukotriene B4 to enhance the response of Toll-like receptor (TLR), RIG-I-like receptor (RLR), and NOD-like receptor (NLR) when stimulated simultaneously with respective proper ligands. The use in combination of LTB4 with those ligands is useful to potentiate immune response for the treatment of autoimmune diseases, immunosuppressive diseases, as well as immunological disorders.Type: ApplicationFiled: June 20, 2011Publication date: September 12, 2013Applicant: UNIVERSITE DE LAVALInventors: Jean Gosselin, Eric Gaudreault
-
Patent number: 8524659Abstract: The present invention provides a RNA virus-derived peptides with modified side chains, wherein the side chains of the RNA virus-derived peptide are modified by altering the side-chain length or charges thereof such that the RNA virus-derived peptide has a high binding affinity for viral RNA and an high cellular uptake capability. The present invention also provides a composition for inhibiting RNA virus wherein the RNA virus-derived peptide can effectively inhibit viral self-replication and treat related diseases by its high affinity for viral RNA. A drug delivery carrier is also provided, wherein the RNA virus-derived peptides can carry desired drugs to the intracellular target due to its cellular uptake capability and thereby enhances the drug-delivery and treating efficiency.Type: GrantFiled: April 5, 2012Date of Patent: September 3, 2013Assignee: National Taiwan UniversityInventors: Richard Ping Cheng, Cheng-Hsun Wu, Ming-Huei Weng, Li-Min Huang
-
Patent number: 8524660Abstract: The invention relates to novel polyalkylene glycol compounds and methods of using them. In particular, compounds comprising a novel polyethylene glycol conjugate are used alone, or in combination with antiviral agents to treat a viral infection, such as chronic hepatitis C.Type: GrantFiled: September 12, 2011Date of Patent: September 3, 2013Assignee: Biogen Idec MA Inc.Inventors: KoChung Lin, R. Blake Pepinsky, Ling Ling Chen, Donna M. Hess, Edward Y. Lin, Russell C. Petter, Darren P. Baker
-
Publication number: 20130217616Abstract: The present invention relates to novel chimeric molecules of ficolin-associated polypeptides, such as fusion polypeptides for the use in the treatment of conditions associated with inflammation, apoptosis, autoimmunity, coagulation, thrombotic or coagulopathic related diseases. The present invention further relates to nucleic acid molecules encoding such fusion polypeptides, vectors and host cells used in the production of the fusion polypeptides.Type: ApplicationFiled: March 4, 2011Publication date: August 22, 2013Inventors: Peter Garred, Tina Hummelshøj Glue, Mikkel-Ole Skjødt
-
Publication number: 20130209464Abstract: A polypeptide is provided that comprises an actinohivin variant polypeptide having an amino acid sequence selected from SEQ ID NOS: 4-12. The polypeptide can be provided as part of a fusion protein that includes the actinohivin variant polypeptide and either a fragment crystallizable domain of an antibody (Fc), a fragment antigen-binding domain of an antibody (Fab), or a single chain variable fragment of an antibody (scFv). Isolated nucleic acid molecules encoding the polypeptides are also provided along with vectors and plant cells capable of expressing the polypeptides. Methods of treating an infection of a subject by an enveloped virus are further provided and include administering an effective amount of the polypeptides to a subject.Type: ApplicationFiled: July 7, 2011Publication date: August 15, 2013Applicant: UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INCInventors: Nobuyuki Matoba, Adam Husk, Sudha Sankaran
-
Publication number: 20130210704Abstract: The present invention relates to a compound of the Formula (I)): or pharmaceutically acceptable salt thereof, wherein the symbols are as defined in the specification; a pharmaceutical composition comprising the same, a method for treating or preventing viral infections, inflammation, dry eye, central nervous disorders, cardiovascular diseases, cancer, obesity, diabetes, muscular dystrophy, and hair loss.Type: ApplicationFiled: March 15, 2013Publication date: August 15, 2013Applicant: S&T GLOBAL INC.Inventor: S&T Global Inc.
-
Publication number: 20130209487Abstract: The invention includes compositions and methods for regulating p110 delta in an avian species. The invention includes inhibiting p110 delta, a component of p110 delta signaling pathway, or any combination thereof in an avian species as an anti-viral therapeutic approach for treating virus infection.Type: ApplicationFiled: June 30, 2011Publication date: August 15, 2013Applicant: Philadelphia Health & Education Corporation d/b/a Drexel University College of MedicineInventor: Peter D. Katsikis
-
Publication number: 20130209403Abstract: The invention relates to Phospholipase A2 (hereinafter also referred to as PLA2) inhibitors for use in the treatment or prevention of flavivirus infection, in particular an infection with a flavivirus of the genus Flavi or the genus Hepaci. The invention also provides a pharmaceutical formulation for use in the treatment or prevention of an infection with a flavivirus of the genus Flavi or the genus Hepaci and a method of preventing or treating an infection with a flavivirus of the genus Flavi or the genus Hepaci.Type: ApplicationFiled: September 8, 2011Publication date: August 15, 2013Applicants: Ruprecht-Karls-Universitaet, Twincore Zentrum fuer Experimentelle and Klinische Infektionsforschung GmbHInventors: Nicolas Menzel, Thomas Pietschmann, Ralf Bartenschlager, Wolfgang Fischl
-
Publication number: 20130203655Abstract: The present invention provides methods to prevent or treat flavivirus infection, and assays for identifying agents which treat flavivirus infection. The present invention also provides compositions for preventing flavivirus infection and a kit for screening an agent that prevents or treats viral infection.Type: ApplicationFiled: February 9, 2011Publication date: August 8, 2013Inventors: Margaret Kielian, Aihua Zheng
-
Publication number: 20130205416Abstract: The present invention provides an agent, in particular a peptide, of formula A, comprising an amino acid sequence X1-X2-X3-X4-X5-X6 (SEQ ID NO 1) wherein X1 can be phenylalanine, isoleucine or tryptophan; X2 can be leucine or phenylalanine or alanine; X3 can be tyrosine or valine; X4 can be leucine, phenylalanine or isoleucine; 10 X5 can be phenyalanine or alanine; and X6 can be valine, arginine or tyrosine, or a fragment or variant of the peptide, wherein said peptide fragment or variant is capable of specifically binding to haemagglutinin, to inhibit the binding of a virus having haemagglutinin on its surface, for use in the treatment of a virus, for example influenza.Type: ApplicationFiled: July 28, 2011Publication date: August 8, 2013Inventors: Anthony Nash, Bernadette Dutia, Mark Stevens